A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.

被引：0
作者：
Shaikh, Saba
Zang, Yan
Hanmer, Janel
Wang, Hong
Lin, Yan
Davar, Diwakar
Zarour, Hassane M.
Kirkwood, John M.
Najjar, Yana G.
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21506
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
    Sullivan, Ryan J.
    Hamid, Omid
    Gonzalez, Rene
    Infante, Jeffrey R.
    Patel, Manish R.
    Hodi, F. Stephen
    Lewis, Karl D.
    Tawbi, Hussein A.
    Hernandez, Genevive
    Wongchenko, Matthew J.
    Chang, YiMeng
    Roberts, Louise
    Ballinger, Marcus
    Yan, Yibing
    Cha, Edward
    Hwu, Patrick
    NATURE MEDICINE, 2019, 25 (06) : 929 - +
  • [12] A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
    Ester Simeone
    Giosuè Scognamiglio
    Mariaelena Capone
    Diana Giannarelli
    Antonio M. Grimaldi
    Domenico Mallardo
    Gabriele Madonna
    Marcello Curvietto
    Assunta Esposito
    Fabio Sandomenico
    Francesco Sabbatino
    Nicholas L. Bayless
    Sarah Warren
    SuFey Ong
    Gerardo Botti
    Keith T. Flaherty
    Soldano Ferrone
    Paolo A. Ascierto
    Journal of Translational Medicine, 19
  • [13] A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.
    Mehnert, Janice M.
    Semlani, Neha
    Wen, Yvonne
    Tan, Antoinette R.
    Moss, Rebecca Anne
    Adams, Shari
    Stein, Mark N.
    Ross, Mikel
    Kane, Michael P.
    Gibbon, Darlene
    Wright, John Joseph
    Aisner, Joseph
    Chen, Suzie
    Goydos, James S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [14] Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
    Hopkins, Ashley M.
    Van Dyk, Madele
    Rowland, Andrew
    Sorich, Michael J.
    PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (04) : 576 - 583
  • [15] Early on-therapy arthralgia predicts improved response and survival in advanced melanoma patients treated with vemurafenib and vemurafenib plus cobimetinib: A pooled analysis of clinical trial data
    Hopkins, Ashley M.
    Dyk, Madele V.
    Rowland, Andrew
    Sorich, Michael J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 187 - 187
  • [16] A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma.
    Algazi, Alain Patrick
    Posch, Christian
    Ortiz-Urda, Susana
    Cockerill, Alyson
    Munster, Pamela N.
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [17] A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
    Lopez-Martin, Jose A.
    Berrocal, Alfonso
    Gonzalez-Cao, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [18] Vemurafenib in patients with metastatic malignant melanoma.
    Ocvirk, Janja
    Mesti, Tanja
    Boc, Marko
    Rebersek, Martina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [19] Treatment with vemurafenib in patients with metastatic melanoma.
    Ocvirk, Janja
    Boc, Marko
    Mesti, Tanja
    Rebersek, Martina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [20] Phase I trial of imatinib and temozolomide in patients with metastatic melanoma.
    Schuchter, L
    Flaherty, K
    Davidson, R
    Cavallaro, L
    Hendricks, M
    Deming, P
    Recio, A
    Tuveson, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 728S - 728S
12345